Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-10-29
2010-06-22
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S142100, C424S139100, C530S388300, C530S387900
Reexamination Certificate
active
07740852
ABSTRACT:
Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
REFERENCES:
patent: 7579446 (2009-08-01), Bakker et al.
patent: 2004/0013672 (2004-01-01), Hooper et al.
patent: 2008/0070799 (2008-03-01), Bakker et al.
patent: A-71982/91 (1991-05-01), None
patent: 7198291 (1991-09-01), None
patent: 0 402 029 (1990-12-01), None
patent: 0402029 (1990-12-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 03/016501 (2003-02-01), None
patent: WO 2004/009618 (2004-01-01), None
patent: WO 2005/118644 (2005-12-01), None
Benmansour et al (Journal of Virology 65:4198-4203, 1991).
Dietzschold et al (Journal of Virology 64:3087-3090, 1990).
Paul, Fundamental Immunology, (textbook), 1993, pp. 292-295.
Lang et al (Biologicals 26:7-15, 1998).
Prosniak et al (Journal of Infectious Diseases 187:53-56, 2003).
Kramer et al., Abstract, Immunity to infection: The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries, Eur. J. Immunol., 35: 2131-2145 (2005), (Abstract only).
Schumacher et al. “Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies.”J. Clin. Invest.84:971-975 (1989).
Paul, Fundamental Immunology, (textbook), 1993, pp. 292-295, Lippincott-Raven Publishers, Philadelphia, PA.
#PCT International Search Report, PCT/EP2005/052410, dated Jan. 9, 2006.
#PCT International Preliminary Report on Patentability, PCT/EP2005/052410, dated Aug. 28, 2006.
#Prosniak et al., “Development of a Cocktail of Recombinant-Expressed Human Rabies Virus-Neutralizing Monoclonal Antibodies for Postexposure Prophylaxis of Rabies,” Journal of Infectious Diseases, Jul. 1, 2003, pp. 53-56, vol. 188.
#Database Genbank NCBI; Jun. 26, 2003, Prosniak, M. et al., “Homo sapieansanti-rabies S057 immunoglobul in heavy chain mRNA” XP 002356864, retrieved from http://www.ncbi.nlr.nih.gov, Database accession No. AY172957.
#Database Genbank NCBI; Jun. 26, 2003, Prosniak, M. et al., “Homo sapieansanti-rabies S057 immunoglobul in lambda light chain mRNA” XP 002356865, retrieved from http://www.ncbi.nlr.nih.gov, Database accession No. AY172960.
#Champion et al., “The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure,” Journal of Immunological Methods, 2000, pp. 81-90, vol. 235.
#Dietzschold et al., “Biological Characterization of Human Monoclonal Antibodies to Rabies Virus,” Journal of Virology, Jun. 1990, pp. 3087-3090, vol. 64, No. 6.
#Hanlon et al., “Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis,” Vaccine, 2001, pp. 3834-3842, vol. 19.
#Jones et al., “High-level Expression of Recombinant IgG in the Human Cell Line Per.C6,” Biotechnol. Prog., 2003, pp. 163-168, vol. 19.
#De Kruif et al., “Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions,” J. Mol. Biol., 1995, pp. 97-105, vol. 248.
De Haard et al., A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies, Journal of Biological Chemistry, 1999, pp. 18218-18230, vol. 274, No. 26.
Ikematsu e4et, Sequences of the Vh genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VhIII segments and somatic hypermutation, The Journal of Immunology, 1993, pp. 1325-1337, vol. 150.
Leucht et al., The B cell superantigen-like interation of intravenous immunoglobulin (IVIG) with Fab fragments of Vh 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy, Clinical Immunology, 2001, pp. 18-29, vol. 99.
Office Action for U.S. Appl. No. 11/980,237 dated May 29, 2009.
Marissen et al., Novel Rabies Virus-Neutralizing Epitope Recognized by Human Monoclonal Antibody: Fine Mapping and Escape Mutant Analysis, Journal of Virology, Apr. 2005, pp. 4672-4678, vol. 79, No. 8.
U.S. Appl. No. 12/589,181, filed Oct. 19, 2009 Logtenberg et al. Antibody Producing Non-Human Mammals.
U.S. Appl. No. 12/383,330, filed Mar. 23, 2009 Bakker et al. Agonistic Binding Molecules to the Human OX40 Receptor.
U.S. Appl. No. 12/590,973, filed Nov. 16, 2009 ter Meulen et al. Binding Molecules Against SARS-Coronavirus and Uses Thereof.
U.S. Appl. No. 12/227,116, filed Nov. 7, 2008 Throsby et al. Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof.
U.S. Appl. No. 12/227,029, filed Nov. 5, 2008 Throsby et al. Human Binding Molecules Having Killing Activity Against Staphylococci and Uses Thereof.
U.S. Appl. No. 12/310,812, filed Mar. 6, 2009 van den Brink et al. Human Binding Molecules Capable of Neutralizing Influenza Virus H5N1 and Uses Thereof.
U.S. Appl. No. 12/459,661, filed Jul. 6, 2009 Bakker et al. Binding Molecules Capable of Neutralizing Rabies Virus and Uses Thereof.
U.S. Appl. No. 12/312,967, filed Jun. 2, 2009 Bakker et al. Liquid Anti-Rabies Antibody Formulations.
Bakker Alexander Berthold Hendrik
De Kruif Cornelis Adriaan
Kramer Robert Arjen
Marissen Willem Egbert
Crucell Holland B.V.
Mosher Mary E
TraskBritt
LandOfFree
Binding molecules capable of neutralizing rabies virus and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding molecules capable of neutralizing rabies virus and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding molecules capable of neutralizing rabies virus and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186151